Day: August 5, 2025

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateThree active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer’s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 2027...

–– Launch of ORLYNVAHTM Expected August 2025— –-Cash Runway into 2026– –Company to host conference call today at 8:30amET– DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. “We are on track to launch ORLYNVAH™ this month for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “We’re proud to introduce the first branded antibiotic for uUTIs in over 25 years—a critical milestone as rising antimicrobial resistance...

SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from...

FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors reinforces significant potential in NSCLC Selective CBP degrader on track for IND-enabling studies, targeting an IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $198.7 million as of June 30, 2025; cash runway into 2028 CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP-1 development candidate In July, secured up to $500 million in senior secured credit to advance pipeline Presented compelling two-year F4c data at EASL Congress; provides estimates for U.S. F4c MASH patient population Received positive CHMP opinion recommending approval of Rezdiffra for the treatment of MASH in Europe Appointed Dan Brennan to Board of Directors Reports cash, cash equivalents, restricted cash and marketable securities of $802.0 million as of June 30, 2025 Company to host conference call today, Aug. 5, 2025, at 8 a.m. EDTCONSHOHOCKEN, Pa., Aug. 05, 2025...

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026 Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 months Ended the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facilityZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company...

Marks next phase of industrial-scale deployment for aluminum sector energy transition. MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces that it has signed an additional contract with Constellium, one of the world’s largest aluminum transformation and recycling companies, for the purchase of plasma torch technology and related peripheral components to be implemented in an aluminum remelting furnace as part of a broader decarbonization effort. The financial terms of the...

PHILADELPHIA, Aug. 05, 2025 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI), a global, market-leading provider of environmental solutions for industrial and specialty waste streams, today announced that its Board of Directors has authorized management to conduct a formal process to evaluate and explore strategic alternatives aimed at unlocking shareholder value. The Company is evaluating a wide range of value creation alternatives including but not limited to a tax-efficient sale or separation of the Clean Earth business, along with the continued execution of the Company’s business plan. “As we seek to close the persistent gap between Enviri’s public market valuation and the company’s sum-of-the-parts value, the Board has authorized a comprehensive review of strategic alternatives,” said Enviri Chairman and CEO Nick Grasberger....